Get 20M+ Full-Text Papers For Less Than $1.50/day. Start a 14-Day Trial for You or Your Team.

Learn More →

La malattia di Behçet

La malattia di Behçet Behçet’s disease (BD) is a vasculitis mainly affecting populations living along the ancient “Silk Route”, with a prevalence of 10–400 cases every 100.000 persons. It is associated with the histocompatibility antigen HLAB51 and is driven by T cell activation. Clinically, BD is characterised by recurrent episodes of oral ulcers, genital ulcers, skin lesions, eye lesions, arthritis, thrombophlebitis, and, less commonly, gastrointestinal, neurological and pulmonary involvement. Superficial and deep thrombophlebitis are the most common vascular features of BD. They are due to inflammation of the vessel wall. Arteries, which are much less commonly involved, may develop aneurysms or occlusions. BD therapy is based on the following agents: corticosteroids, azathioprine, cyclosporine A, colchicine, methotrexate, cyclophosphamide and TNF antagonists. The treatment should be tailored to the individual patient according to type and severity of involvement. Anticoagulant and antiplatelet agents should not be used in the therapy of BD thrombosis. http://www.deepdyve.com/assets/images/DeepDyve-Logo-lg.png Archivio di Ortopedia e Reumatologia Springer Journals

La malattia di Behçet

Marchesoni, A.
Archivio di Ortopedia e Reumatologia , Volume 121 (1) – Jan 10, 2011
Download PDF
3 pages

Loading next page...
 
/lp/springer-journals/la-malattia-di-beh-et-sNBySeXyuh
Publisher
Springer Journals
Copyright
Copyright © 2010 by Springer-Verlag Italia
Subject
Medicine & Public Health; Orthopedics
ISSN
0390-7368
eISSN
1592-7113
DOI
10.1007/s10261-010-0005-z
Publisher site
See Article on Publisher Site

Abstract

Behçet’s disease (BD) is a vasculitis mainly affecting populations living along the ancient “Silk Route”, with a prevalence of 10–400 cases every 100.000 persons. It is associated with the histocompatibility antigen HLAB51 and is driven by T cell activation. Clinically, BD is characterised by recurrent episodes of oral ulcers, genital ulcers, skin lesions, eye lesions, arthritis, thrombophlebitis, and, less commonly, gastrointestinal, neurological and pulmonary involvement. Superficial and deep thrombophlebitis are the most common vascular features of BD. They are due to inflammation of the vessel wall. Arteries, which are much less commonly involved, may develop aneurysms or occlusions. BD therapy is based on the following agents: corticosteroids, azathioprine, cyclosporine A, colchicine, methotrexate, cyclophosphamide and TNF antagonists. The treatment should be tailored to the individual patient according to type and severity of involvement. Anticoagulant and antiplatelet agents should not be used in the therapy of BD thrombosis.

Journal

Archivio di Ortopedia e Reumatologia – Springer Journals

Published: Jan 10, 2011

References

  • Über rezidivierende, aphthöse, durch ein Virus verursachte Geschwüre im Mund, am Auge und an den Genitalien
    Behçet, H.
  • Considerations sur le lésions aphteuses de la bouche et des parties génitales ainsi que sur les manifestations oculaires d’origine probablement parasitaire et observations concernant leur foyer d’infection
    Behçet, H.
  • Behçet’s disease — a contemporary review
    Mendes, D.; Correia, M.; Barbedo, M.
  • Epidemiology and clinical course of Behçet’s disease in the Reggio Emilia area of Northern Italy: a seventeen-year population-based study
    Salvarani, C.; Pipitone, N.; Catanoso, M.G.
  • Whole-genome screening for susceptibility genes in multicase families with Behçet’s disease
    Karasneh, J.; Gül, A.; Ollier, W.E.
  • Behçet’s disease
    Krause, I.; Weinberger, A.
  • Role of IL-12B promoter polymorphism in Adamantiades-Behçet’s disease susceptibility: An involvement of Th1 immunoreactivity against Streptococcus sanguinis antigen
    Yanagihori, H.; Oyama, N.; Nakamura, K.
  • Proteomic surveillance of autoimmunity in Behçet’s disease with uveitis: selenium binding protein is a novel autoantigen in Behçet’s disease
    Okunuki, Y.; Usui, Y.; Takeuchi, M.
  • Mucocutaneous lesions of Behçet’s disease
    Alpsoy, E.; Zouboulis, C.C.; Ehrlich, G.E.
  • Thrombophilic risk factors and homocysteine levels in Behçet’s disease in eastern Spain and their association with thrombotic events
    Ricart, J.M.; Vayá, A.; Todolí, J.
  • Homocysteine: an activity marker in Behçet’s disease?
    Sarican, T.; Ayabakan, H.; Turkmen, S.
  • Mechanisms of thrombus formation
    Furie, B.; Furie, B.C.
  • Tissue factor, the blood, and the arterial wall
    Rauch, U.; Nemerson, Y.
  • CD40 ligand on activated platelets triggers an inflammatory reaction of endothelial cells
    Henn, V.; Slupsky, J.R.; Gräfe, M.
  • HLAB51/B5 and the risk of Behçet’s disease: a systematic review and meta-analysis of case-control genetic association studies
    Menthon, M.; Lavalley, M.P.; Maldini, C.
  • Cardiovascular Behçet disease: the variable findings of rare complications with CT angiography and conventional angiography and its interventional management
    Cho, Y.K.; Lee, W.; Choi, S.I.
  • Behçet disease
    Suzuki, K.; Suzuki, N.
  • Criteria for diagnosis of Behçet’s disease
  • Management of Behçet disease: a systematic literature review for the European League Against Rheumatism evidence-based recommendations for the management of Behçet disease
    Hatemi, G.; Silman, A.; Bang, D.
  • EULAR recommendations for the management of Behçet disease
    Hatemi, G.; Silman, A.; Bang, D.